Clinical Trial Update: Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients [Phase 4]

View source ↗

Summary

Phase 4 trial examining whether switching from efavirenz to raltegravir affects vascular function and bone markers in HIV-infected patients; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Isentress (Raltegravir)
• Sustiva (efavirenz)

Snippet

Sponsor: Indiana University | Conditions: HIV | Phase 4 | Status: COMPLETED | Results posted: 2013-10-24